/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Adial Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.316 0.007(0.7%) ADIL at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 0.3021
Highest Today 0.3149
Today’s Open 0.3021
Prev. Close 0.3129
52 Week High 1.30
52 Week Low 0.22
Day’s Range: Low 0.3021 High 0.3149
52-Week Range: Low 0.22 High 1.30
1 day return -
1 Week return -0.35
1 month return -3.78
3 month return -9.33
6 month return -42.6
1 year return -73.93
3 year return -95.19
5 year return -99.38
10 year return -

Institutional Holdings

Geode Capital Management, LLC 0.32

Manchester Capital Management LLC 0.22

Fidelity Extended Market Index 0.18

BlackRock Inc 0.13

Jane Street Group LLC 0.11

HRT FINANCIAL LLC 0.09

Extended Equity Market Fund K 0.08

Vanguard Group Inc 0.06

UBS Group AG 0.06

Spartan Extended Market Index Pool F 0.06

Two Sigma Investments LLC 0.05

Fidelity Series Total Market Index 0.04

Vanguard Institutional Extnd Mkt Idx Tr 0.04

Fidelity Total Market Index 0.04

Citigroup Inc 0.02

Stone House Investment Management, LLC 0.01

Extended Equity Market Fund M 0.01

Tower Research Capital LLC 0.01

SBI Securities Co Ltd 0.01

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

State St US Extended Mkt Indx NL Cl C 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Wells Fargo & Co 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Bank of America Corp 0.00

Northern Trust Wilshire 5000 0.00

Abound Wealth Management 0.00

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.00

Citadel Advisors Llc 0.00

Morgan Stanley - Brokerage Accounts 0.00

Renaissance Technologies Corp 0.00

Virtu Financial LLC 0.00

Market Status

Strong Buy: 2

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 7.51 M

PB Ratio 1.6698

PE Ratio 0.0

Enterprise Value 2.92 M

Total Assets 5.04 M

Volume 245308

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-6069703 -6.1M, FY22:-12731416 -12.7M, FY21:-19423326 -19.4M, FY20:-10860495 -10.9M, FY19:-8591429 -8.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-141 -0.0M, Q2/2025:-141 -0.0M, Q1/2025:-141 -0.0M, Q3/2024:null 0.0M, Q2/2024:-141 -0.0M

Quarterly Net worth Q3/2025:-1793651 -1.8M, Q2/2025:-1958556 -2.0M, Q1/2025:-2228801 -2.2M, Q3/2024:-2191803 -2.2M, Q2/2024:-2458298 -2.5M

Fund house & investment objective

Company Information Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

Organisation Biotechnology

Employees 5

Industry Biotechnology

CEO Mr. Cary John Claiborne MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow